ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Effect of Micafungin Bridging on Prevention of Invasive Candidiasis Post Lung Transplantation

C. Baladad1, M. Converse1, K. DeSear1, S. Karimi1, E. Rubido1, G. El Helou2, T. Pasley1

1Pharmacy, University of Florida Health, Shands, Gainesville, FL, 2Infectious Diseases, University of Florida Health, Shands, Gainesville, FL

Meeting: 2022 American Transplant Congress

Abstract number: 1669

Keywords: Fungal infection, Lung infection, Lung transplantation, Prophylaxis

Topic: Clinical Science » Pharmacy » 30 - Non-Organ Specific: Clinical Pharmacy/Transplant Pharmacotherapy

Session Information

Session Name: Pharmacy II

Session Type: Poster Abstract

Date: Tuesday, June 7, 2022

Session Time: 7:00pm-8:00pm

 Presentation Time: 7:00pm-8:00pm

Location: Hynes Halls C & D

*Purpose: This study aims to determine the effect of micafungin, added as a bridging agent to azole antifungal prophylaxis, in lung transplantation patients with positive Candida respiratory cultures in the first 6 weeks post-transplant.

*Methods: This is a single-center, retrospective cohort study conducted via chart review of lung transplant recipients between August 2017 and August 2020. Included patients were adult lung transplant recipients with positive Candida cultures pre-operatively (donor or recipient) or within 6 weeks post-operatively. Patients were divided into 2 cohorts: historical cohort with azole monotherapy and current cohort, where our institutional protocol included a micafungin bridge until azole levels are in therapeutic range whenever a respiratory culture is positive for Candida.

The primary outcome was a composite of proven or probable invasive fungal infections defined by the Revised 2020 European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Secondary outcomes included proven invasive fungal infections, probable invasive fungal infections, any adverse bronchoscopy finding (i.e., anastomotic dehiscence, sloughing, or severe ischemia/necrosis), sternal wound dehiscence, bacterial and/or fungal chest wall infection, fungal empyema, intensive care unit length of stay, post-transplant hospital length of stay, and 90-day all-cause mortality.

*Results: A total of 117 patients were included in the study: 68 in the unbridged cohort and 49 in the bridged cohort. The two cohorts appear similar; however, 32.7% of patients in the bridged group required extracorporeal membrane oxygenation, compared to 16.2% in the unbridged group.

*Conclusions: In combination with an azole antifungal, micafungin did not prevent invasive fungal infections in post-operative lung transplant patients with cultures positive for Candida species.

Table 1: Primary and secondary endpoints
Endpoints Unbridged (n=68) Bridged (n=49) P-value
Proven or probable IFI, n (%) 0 (0) 5 (10.2) 0.011
Proven IFI, n (%) 0 (0) 5 (10.2) 0.011
Adverse bronchoscopic finding, n (%) 16 (23.5) 13 (26.5) 0.711
Chest wall infections, n (%) 2 (2.9) 0 (0) 0.509
Sternal wound dehiscence, n (%) 9 (13.2) 2 (4.1) 0.117
Fungal empyema, n (%) 0 (0) 3 (6) 0.071
90-day all-cause mortality, n (%) 1 (1.4) 2 (4.1) 0.571

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Baladad C, Converse M, DeSear K, Karimi S, Rubido E, Helou GEl, Pasley T. Effect of Micafungin Bridging on Prevention of Invasive Candidiasis Post Lung Transplantation [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/effect-of-micafungin-bridging-on-prevention-of-invasive-candidiasis-post-lung-transplantation/. Accessed May 28, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences